Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 3 Trial to Investigate the Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) at the End of Shelf Life in Healthy Adults in Non-Endemic Country(Ies) for Dengue

NCT03771963 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT03771963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03771963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 3 Trial to Investigate the Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) at the End of Shelf Life in Healthy Adults in Non-Endemic Country(Ies) for Dengue
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
March 28, 2019
Completion date
March 13, 2020
Enrollment
200 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

dengue fever